
Pirtobrutinib Enhances Disease Control in Relapsed CLL/SLL
Photo Credit: iStock.com/Nemes Laszlo Targeted BTK inhibition with pirtobrutinib offers durable disease control and improved safety in relapsed CLL/SLL. In a Phase III Trial study published in June 2025 issue of Journal of Clinical Oncology, …